Literature DB >> 11990518

Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha.

Mats Merup1, Wiveca Aberg, Eva Löfvenberg, Else Svensson, Katarina Engman, Christer Paul, Ann Gardulf.   

Abstract

Sixteen patients with polycythaemia vera or essential thrombocythaemia were treated with interferon-alpha in order to normalize elevated platelets. Patients were followed for 6 months and the frequency and intensity of symptoms and side effects were recorded before and during the study period by the patients and by the doctor. Health-related quality of life was also assessed. The most frequently reported pretreatment symptoms were fatigue, headache and muscle pain. The intensity of fatigue initially increased during treatment and there was no relief of any of the three most frequent symptoms during the treatment period. Common interferon-related symptoms such as fever and chills were most frequently reported after one week. After one month of treatment, symptoms related to the gastrointestinal tract reached a peak. Two patients discontinued treatment during the study period. Another patient suffered severe depression after the study period when still on interferon. There was no difference between the frequency of symptoms recorded by the doctor and that reported by the patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11990518     DOI: 10.1080/028418602317314064

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Clinical features of adverse reactions associated with telbivudine.

Authors:  Xue-Song Zhang; Rui Jin; Shi-Bin Zhang; Ming-Ling Tao
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 2.  The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 3.  Headache in essential thrombocythaemia.

Authors:  R Frewin; A Dowson
Journal:  Int J Clin Pract       Date:  2012-08-14       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.